VTRS / Viatris Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 VIATRIS INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact na

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance •Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business •Positive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline •Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share Buybacks •Reiterates 2025 Financial Guidance Ranges Across all Metrics and Expects to be in the Top Half of the Range for Total Revenues and Adjusted EPS [1] PITTSBURGH – August 7, 2025 – Viatris Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 VIATRIS INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Exhibit 99.1 Viatris Announces Appointment of David Simmons to the Company's Board of Directors PITTSBURGH – August 5, 2025 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris’ Board of Directors. Simmons has deep pharmaceutical industry experience, as well as extensive executive, board, and capital marke

VIATRIS INC. SUBORDINATED INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as amended* Reflected in Indenture

Exhibit 4.12 VIATRIS INC. SUBORDINATED INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as amended* Reflected in Indenture Trust Indenture Act Section Indenture Section 310 (a) (1) 7.09 (a) (2) 7.09 (a) (3) N.A. (a) (4) N.A. (a) (5) 7.09 (b) 7.03; 7.09 311 (a) 7.11 (b) 7.11 312 (a) 2.07 (b) 12

Consolidated Report of Condition of

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Jurisdiction

VIATRIS INC. JUNIOR SUBORDINATED INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as Reflected in Indenture

Exhibit 4.13 VIATRIS INC. JUNIOR SUBORDINATED INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as amended* Reflected in Indenture Trust Indenture Act Section Indenture Section 310 (a) (1) 7.09 (a) (2) 7.09 (a) (3) N.A. (a) (4) N.A. (a) (5) 7.09 (b) 7.03; 7.09 311 (a) 7.11 (b) 7.11 312 (a) 2.07

As filed with the Securities and Exchange Commission on May 8, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 8, 2025 Registration No.

[Viatris Letterhead]

Exhibit 10.1 [Viatris Letterhead] February 16, 2024 Dear Corinne: On behalf of Viatris Inc. (the “Company “), I am pleased to confirm the terms of employment offered by the Company in connection with your role as Chief Commercial Officer of the Company effective as of March 1, 2024, (the “Effective Date “). 1.Position. Your position shall be Chief Commercial Officer, and you shall devote your full

Calculation of Filing Fee Tables Form S-3 (Form Type) Viatris Inc. (Exact Name of Registrant as Specified in Its Charter) Mylan Inc. (Exact Name of Registrant as Specified in Its Charter) Mylan II B.V. (Exact Name of Registrant as Specified in Its Ch

Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Viatris Inc. (Exact Name of Registrant as Specified in Its Charter) Mylan Inc. (Exact Name of Registrant as Specified in Its Charter) Mylan II B.V. (Exact Name of Registrant as Specified in Its Charter) Utah Acquisition Sub Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Secu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTE

Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Jurisdiction

VIATRIS INC. SENIOR INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as amended* Reflected in Indenture

Exhibit 4.11 VIATRIS INC. SENIOR INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as amended* Reflected in Indenture Trust Indenture Act Section Indenture Section 310 (a) (1) 7.09 (a) (2) 7.09 (a) (3) N.A. (a) (4) N.A. (a) (5) 7.09 (b) 7.03; 7.09 311 (a) 7.11 (b) 7.11 312 (a) 2.07 (b) 12.05 (c

Parker Poe Adams & Bernstein LLP 620 South Tryon Suite 800 Charlotte, NC 28202 t 704.372.9000 f 704.334.4706 www.parkerpoe.com

Exhibit 5.3 Atlanta, GA Charleston, SC Charlotte, NC Columbia, SC Greenville, SC Raleigh, NC Spartanburg, SC Washington, D.C. May 8, 2025 Viatris Inc. Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Re: The Registration Statement (as defined below) Ladies and Gentlemen: We are Pennsylvania counsel to Mylan Inc., a Pennsylvania corporation (“Company”), and have been asked to prepare

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTE

Exhibit 25.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Jurisdiction

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook •Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business •Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts •Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH – May 8, 2025 – Viatris Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 VIATRIS INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact n

Viatris Announces Appointments of Frank D’Amelio and Michael Severino, M.D., to the Company’s Board of Directors

Exhibit 99.1 Viatris Announces Appointments of Frank D’Amelio and Michael Severino, M.D., to the Company’s Board of Directors Directors Rajiv Malik and Harry Korman to Retire at the End of Their Current Terms PITTSBURGH – May 5, 2025 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Frank D’Amelio and Michael Severino

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from     to     Commission fi

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of December 31, 2024, Viatris Inc.

Subsidiaries as of December 31, 2024

Exhibit 21 Subsidiaries as of December 31, 2024 Name State or Country of Organization Agila Australasia Pty Ltd Australia Alphapharm Pty.

Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance

Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance •Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1] •Reports 2024 Total Revenues of $14.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact name o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

Viatris Inc. Global Insider Trading Policy

Exhibit 19 Viatris Inc. Global Insider Trading Policy APPLICABILITY This Global Insider Trading Policy (the “Policy”) applies globally to Viatris Inc. and all of its subsidiaries and Affiliates around the world (collectively the “Company”), all of the Company’s employees, Officers, members of the Company’s Board of Directors (“Directors”), and consultants, contractors and agents acting on behalf o

Amendment to the Viatris Inc. 2020 Stock Incentive Plan

Exhibit 10.1(b) Amendment to the Viatris Inc. 2020 Stock Incentive Plan WHEREAS, the Company currently maintains and sponsors the 2020 Plan; WHEREAS, Section 13(a) of the 2020 Plan provides that the Board may amend the Plan from time to time, except that shareholder approval shall be required for any amendment that would increase the maximum number of shares of common stock, par value $0.01 per sh

OMNIBUS AMENDMENT NO. 3

Exhibit 2.3(e) OMNIBUS AMENDMENT NO. 3 This OMNIBUS AMENDMENT NO. 3, effective as of December 24, 2024 (this “Amendment”), is by and among Viatris Inc., a Delaware corporation (“Viatris”), Biocon Biologics UK Limited, a U.K. private limited company (“Biocon UK”), Biosimilar Collaborations Ireland Limited, an Irish private limited company (“Biosimilar Collaborations”), Biosimilars Newco Limited, a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 VIATRIS INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of September 30, 2024, Viatris Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 VIATRIS INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Viatris Reports Third Quarter Financial Results for 2024

Viatris Reports Third Quarter Financial Results for 2024 •Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company’s Base Business[1] •Strong New Product Revenues of $133 Million Drove Growth Across Segments •U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒        Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39695 (Commission File Number) 83-43

Second Amended and Restated Revolving Credit Agreement, dated as of September 27, 2024, among Viatris, certain affiliates and subsidiaries of Viatris from time to time party thereto as guarantors, each lender and issuing bank from time to time party thereto and Bank of America, N.A., as administrative agent.*

Exhibit 10.1 EXECUTION VERSION SECOND AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT dated as of September 27, 2024, among VIATRIS INC. as Borrower and the Guarantors from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent and the Lenders and the Issuing Banks from time to time party hereto BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., CITIBANK,

Viatris Announces Cash Tender Offers for Certain Outstanding Notes1

Exhibit 99.1 Viatris Announces Cash Tender Offers for Certain Outstanding Notes1 PITTSBURGH, September 4, 2024 – Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) announced today that it and its subsidiaries, Mylan Inc. (“Mylan”) and Utah Acquisition Sub Inc. (“Utah Acquisition” and, together with Viatris and Mylan, the “Offerors” and each, an “Offeror”), have commenced tender offers (each i

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 Viatris Inc (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact na

Viatris Reports Second Quarter Financial Results for 2024 Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business

Viatris Reports Second Quarter Financial Results for 2024 Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business •Total Revenues of $3.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 VIATRIS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

EX-99.1 Exhibit 99.1 Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors Pittsburgh – June 3, 2024 – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reest

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 VIATRIS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges •Reports Total Revenues of $3.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 VIATRIS INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   For the Fiscal Year Ended December 31, 2023 OR ☐ Transition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   For the Fiscal Year Ended December 31, 2023 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   For the transition period from      to      Commission file number 00

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of December 31, 2023, Viatris Inc.

Exhibit 4.9

Exhibit 4.9 DESCRIPTION OF VIATRIS INC. SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023, our shares of common stock, par value $0.01, are the only securities of Viatris Inc. (“Viatris”, “we”, “our” or “us”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common stock, referred t

SEPARATION AGREEMENT AND RELEASE

Exhibit 10.15 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Anthony Mauro (“Executive”) and Viatris Inc. (together with its affiliates, the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive shall separate from employment with the Company effective as of April 1,

RETIREMENT AND OPERATING CONSULTING AGREEMENT AND RELEASE

Exhibit 10.14 RETIREMENT AND OPERATING CONSULTING AGREEMENT AND RELEASE This Retirement and Consulting Agreement and Release (“Agreement”) is made by and between Rajiv Malik (“Executive”) and Viatris Inc. (together with its affiliates, the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive shall retire from employment with t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact name o

December 15, 2023

Exhibit 10.13 December 15, 2023 Theodora (Doretta) Mistras 105 West 29th Street, Suite 32D New York, NY10001 Dear Doretta: On behalf of Viatris Inc. (the “Company”), I am pleased to confirm the terms of employment offered by the Company in connection with your future role as Chief Financial Officer of the Company. 1.Position. You shall join the Company on January 1, 2024 (the “Effective Date”) as

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance •Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] •Reports 2023 Total Revenues of $15.

Subsidiaries as of December 31, 2023

Exhibit 21 Subsidiaries as of December 31, 2023 Name State or Country of Organization Agila Australasia Pty Ltd Australia Alphapharm Pty.

OMNIBUS AMENDMENT NO. 2

Exhibit 2.3(d) OMNIBUS AMENDMENT NO. 2 This OMNIBUS AMENDMENT NO. 2, effective as of December 19, 2023 (this “Amendment”), is by and among Viatris Inc., a Delaware corporation (“Viatris”), Biocon Biologics UK Limited, a U.K. private limited company (“Biocon UK”), Biosimilars Newco Limited, a U.K. private limited company (“Biosimilars Newco” and, collectively with Biocon UK, the “Confessing Parties

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIATRIS INC.

Exhibit 3.1(c) CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIATRIS INC. Viatris Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: FIRST: That Article X of the Amended and Restated Certificate of Incorporation of the Corporation,

SEPARATION AGREEMENT AND RELEASE

Exhibit 10.16 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Sanjeev Narula (“Executive”) and Viatris Inc. (together with its affiliates, the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive shall separate from employment with the Company effective as of March 5,

CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIATRIS INC.

Exhibit 3.1(d) CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIATRIS INC. Viatris Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: FIRST: That Article IX, Section 9.01 of the Amended and Restated Certificate of Incorporation of t

Viatris Inc. Incentive-Based Compensation Recovery Policy Effective December 1, 2023

Exhibit 97 Viatris Inc. Incentive-Based Compensation Recovery Policy Effective December 1, 2023 Scope: This Incentive-Based Compensation Recovery Policy (the “Policy”) of Viatris Inc. (the “Company”) applies to each Specified Officer as set forth herein. Purpose: To establish a policy providing for the recovery of erroneously awarded incentive-based compensation as required by Section 10D of the S

VTRS / Viatris Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Viatris Inc Title of Class of Securities: Common Stock CUSIP Number: 92556V106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

Transaction Agreement, dated as of January 29, 2024, by and among Cooper Consumer Health SAS, Cooper Consumer Health IT S.r.l., Viatris Inc., Viatris Italia S.r.l. and Ipex AB*

Exhibit 2.1 EXECUTION VERSION TRANSACTION AGREEMENT by and among COOPER CONSUMER HEALTH SAS, COOPER CONSUMER HEALH IT SRL, VIATRIS INC., VIATRIS ITALIA S.R.L. and IPEX AB Entered into and delivered as of January 29, 2024 TABLE OF CONTENTS Page Article I The Closing Section 1.01. Closing 2 Section 1.02. The Acquisition 2 Section 1.03. Purchase Price Allocation 3 Section 1.04. Transactions to be Eff

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (C

Robert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders

EX-99.1 Exhibit 99.1 Robert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders The End of One Era and The Beginning of Another Dear Fellow Shareholders, Over twenty years ago when I first joined our legacy company Mylan, we identified an unmet need in the global healthcare industry and set out to fill it by building a true one-of-a-kind global platform uniquely positioned to bridg

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora “Doretta” Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer Company thanks Sanjeev Naru

EX-99.1 Exhibit 99.1 Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora “Doretta” Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer Company thanks Sanjeev Narula for his role in the successful execution of Viatris’ Phase 1 strategy; Narula will support a smooth CFO transition prior to hi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

Amended and Restated Bylaws of Viatris Inc., effective as of December 15, 2023.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VIATRIS INC. Effective as of December 15, 2023 Table of Contents Page ARTICLE I STOCKHOLDERS’ MEETINGS 1 Section 1.1 Place of Meetings 1 Section 1.2 Annual Meetings 1 Section 1.3 Special Meetings 1 Section 1.4 Notice 2 Section 1.5 Quorum; Adjournments; Postponement 2 Section 1.6 Proxies; Voting 3 Section 1.7 Inspectors of Election 4 Section 1.8 Lis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exa

Cooper Consumer Health Société par actions simplifiée Share capital: €5.916.923,85 Registered office: place Lucien Auvert, 77000 Melun 897 662 631 R.C.S Melun

Exhibit 2.1 EXECUTION VERSION Cooper Consumer Health Société par actions simplifiée Share capital: €5.916.923,85 Registered office: place Lucien Auvert, 77000 Melun 897 662 631 R.C.S Melun Strictly Confidential October 1st, 2023 VIATRIS INC. (the “Beneficiary”) Re: Put Option Dear Madam or Sir: Reference is made to our recent discussions relating to the contemplated acquisition of the Business (co

Operational Change(1) (3)

Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] •Reports Total Revenues of $3.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Rajiv Malik to retire as President of Viatris effective April 1, 2024

Exhibit 99.1 Rajiv Malik to retire as President of Viatris effective April 1, 2024 Pittsburgh – Oct. 20, 2023 – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik, will be retiring as an executive of the Company effective April 1, 2024. Malik is a nearly 40-year pharmaceutical industry veteran who has been responsible for the day-to-day operat

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Forward Looking Statements This presentation contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include,

Divestitures Announcement October 1, 2023 Exhibit 99.2 Forward Looking Statements This presentation contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, Viatris announces agreements on remaining planned divestitures; upon closi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2023 VIATRIS INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA

Exhibit 99.1 Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA • Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company’s Biosimilars Business, and the Estimated Retained Value are in Line with the Company’s Previously Communicated Range •

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] •Reports Total Revenues of $3.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact na

TRANSITION AND ADVISORY AGREEMENT AND RELEASE

Exhibit 10.2 TRANSITION AND ADVISORY AGREEMENT AND RELEASE This TRANSITION AND ADVISORY AGREEMENT AND RELEASE (this “Agreement”) is entered into and effective as of May 19, 2023, by and between Viatris Inc. (“Viatris” or the “Company”) and Robert J. Coury (“Executive”). WHEREAS, the Executive has served as Executive Chairman of the Company since it became a publicly-traded corporation on November

OMNIBUS AMENDMENT NO. 1

Exhibit 2.1 OMNIBUS AMENDMENT NO. 1 This OMNIBUS AMENDMENT NO. 1, effective as of May 17, 2023 (this “Amendment”), is by and among Viatris Inc., a Delaware corporation (“Viatris”), Biocon Biologics UK Limited, a U.K. private limited company (“Biocon UK”), Biosimilar Collaborations Ireland Limited, an Irish private limited company (“Biosimilar Collaborations”), Biosimilars Newco Limited, a U.K. pri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 VIATRIS INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number

Viatris Announces Appointment of Leo Groothuis to Company’s Board of Directors

EX-99.2 Exhibit 99.2 Viatris Announces Appointment of Leo Groothuis to Company’s Board of Directors PITTSBURGH – May 22, 2023 – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris’ newest member of its board of directors. Groothuis fills the vacancy created by the previous depar

Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year Coury will serve in this new role until the end of 2025

EX-99.1 Exhibit 99.1 Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year Coury will serve in this new role until the end of 2025 Pittsburgh – May 22, 2023 – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that as a result of the strength and stability that Via

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 VIATRIS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number)

LIBOR TRANSITION AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT

Exhibit 10.4 Execution Version LIBOR TRANSITION AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT This LIBOR TRANSITION AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT (this “Amendment”), dated as of April 28, 2023, is among VIATRIS INC., a Delaware corporation (the “Borrower”), certain Affiliates and Subsidiaries of the Borrower from time to time party hereto as Guarantors

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of March 31, 2023, Viatris Inc.

Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] •Reports Total Revenues of $3.

VIATRIS INC. PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT

Exhibit 10.3 VIATRIS INC. PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT THIS PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of [] (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [] (the “Participant”). 1.Grant of Performance-Based Restricted Stock Units. (a)Grant. The Company hereby grants to th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 VIATRIS INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact n

UN I TED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ Transition

UN I TED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIAT

Oyster Point Pharma, Inc. 2021 Inducement Plan.

EX-99.3 Exhibit 99.3 Oyster Point Pharma, Inc. 2021 Inducement Plan Adopted by the Board of Directors: July 30, 2021 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasd

Power of Attorney (included as part of the signature page of this registration statement).

S-8 As filed with the U.S. Securities and Exchange Commission on March 3, 2023 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viatris Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, pa

Oyster Point Pharma, Inc. 2016 Equity Incentive Plan.

EX-99.1 Exhibit 99.1 OYSTER POINT PHARMA, INC. 2016 EQUITY INCENTIVE PLAN (as of February 13, 2019) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permit

Oyster Point Pharma, Inc. 2019 Equity Incentive Plan.

EX-99.2 Exhibit 99.2 OYSTER POINT PHARMA, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive S

Subsidiaries as of December 31, 2022

Exhibit 21 Subsidiaries as of December 31, 2022 Name State or Country of Organization Upjohn Saidal Pharma Algeria Agila Australasia Pty Ltd Australia Alphapharm Pty.

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of December 31, 2022, Viatris Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorp

Form 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation)

Separation Agreement with Michael Goettler, dated February 24, 2023.

EX-10.2 Exhibit 10.2 EXECUTION VERSION SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Michael Goettler (“Executive”) and Viatris Inc. (together with its affiliates, the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive shall separate from employment with the Compa

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact name o

Offer Letter with Scott A. Smith, dated February 24, 2023.

EX-10.1 Exhibit 10.1 EXECUTION VERSION February 24, 2023 Scott A. Smith c/o last address on file with the Company Dear Scott: On behalf of Viatris Inc. (the “Company”), I am pleased to confirm the terms of employment offered by the Company in connection with your role as Chief Executive Officer of the Company effective as of April 1, 2023 (the “Effective Date”). 1. Position. Your position shall be

Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance •Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quarter Impact of the Biosimilars Transaction and Acquired IPR&D •2023 Guidance Midpoint Reflects Revenue Growth Over 2022, Excluding Full-Year Impact of Biosimilars •Reaffirms 2024 Phase 2 Outlook from November 7 Strategic Update •Company Increases Return of Capital to Shareholders by Completing $250 Million in Share Repurchases •Board of Directors Approves 2023 Dividend Policy of Forty-Eight Cents ($0.

Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023 Smith, a seasoned senior healthcare executive, will lead the company’s previously announced Phase 2 strategy and execution Board of Directors thanks Michael Goettler, who

EX-99.1 Exhibit 99.1 Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023 Smith, a seasoned senior healthcare executive, will lead the company’s previously announced Phase 2 strategy and execution Board of Directors thanks Michael Goettler, who will support a smooth transition prior to his departure PITTSBURGH – February 27, 2023 – Viatris Inc. (NASDAQ: VTRS), a global he

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 VIATRIS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

VTRS / Viatris Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02188-viatrisinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Viatris Inc. Title of Class of Securities: Common Stock CUSIP Number: 92556V106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p

Press Release issued by Viatris on January 3, 2023.”

EX-99.(a)(5)(e) Exhibit (a)(5)(E) Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division Division Combines Oyster Point Pharma’s Eye Care Expertise with Famy Life Science’s Phase III-ready Pipeline and Lays Foundation for Viatris to Become a Global Eye Care Leader Acquisitions Have the Potential to Add at Least $1 Billion in Sales by 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off

Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company’s Board of Directors Directors Neil Dimick and Ian Read Retire

Exhibit 99.1 Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company?s Board of Directors Directors Neil Dimick and Ian Read Retire PITTSBURGH ? December 29, 2022 ? Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris? newest members of its board of directors. Smith and Finney

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Co

SC TO-T/A 1 d407536dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) (Names of

Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

Exhibit (a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of OYSTER POINT PHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHA

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, $0.01 PAR VALUE (Title of Class of Securities)

Form of Notice of Guaranteed Delivery.*

Exhibit (a)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of OYSTER POINT PHARMA, INC.

Form of Summary Newspaper Advertisement, as published in The New York Times on December 1, 2022.*

Exhibit (a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

Clean Team Confidentiality Agreement, dated October 21, 2022, by and between Viatris and Oyster Point.*

Exhibit (d)(5) Exhibit (d)(5) EXECUTION VERSION STRICTLY CONFIDENTIAL CLEAN TEAM CONFIDENTIALITY AGREEMENT This Clean Team Confidentiality Agreement (the “Agreement”) is entered into as of October 21, 2022, by and between Viatris Inc.

Tender and Support Agreement, dated November 7, 2022, by and among Viatris, Purchaser, InvOpps IV US, L.P., InvOppsIV, L.P., Jeffrey Nau, Ph.D., M.M.S., New Enterprise Associates 14, L.P., Versant Venture Capital VI, L.P., Versant Vantage I, L.P., Versant Venture Capital IV, L.P. and Versant Side Fund IV, L.P.*

Exhibit (d)(3) Exhibit (d)(3) Execution Version CONFIDENTIAL TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 7, 2022, is by and among Viatris Inc.

Offer to Purchase dated December 1, 2022.*

Exhibit (a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Oyster Point Pharma, Inc.

Form of Letter to Clients for use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

Exhibit (a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of OYSTER POINT PHARMA, INC.

Confidentiality Agreement, dated June 28, 2022, by and between Viatris and Oyster Point.*

Exhibit (d)(4) Exhibit (d)(4) CONFIDENTIALITY AGREEMENT This Confidentiality Agreement (this “Agreement”) is executed and entered into on June 28, 2022 (the “Effective Date”), by and between Viatris Inc.

Form of Letter of Transmittal (including Internal Revenue Service Form W-9).*

Exhibit (a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of OYSTER POINT PHARMA, INC.

Filing Fee Table*

EX-FILING FEES 11 d342841dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) OYSTER POINT PHARMA, INC. (Name of Subject Company (Issuer)) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) (Name of Filing Persons (identifying status as offeror, issuer or other person) Table 1 – Transaction Valuation Transa

Amendment No. 1 to Transaction Agreement, dated as of November 28, 2022, by and between Biocon Biologics Limited and Viatris Inc.*

Exhibit 2.1 AMENDMENT NO. 1 TO TRANSACTION AGREEMENT November 28, 2022 Reference is hereby made to that certain Transaction Agreement, dated as of February 27, 2022 (as amended from time to time, the ?Agreement?), by and between Biocon Biologics Limited, a public limited company incorporated under the Indian Companies Act, 2013 (?Buyer?), and Viatris Inc., a Delaware corporation (?Seller Parent?).

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Viatris Inc. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

Viatris Completes Biosimilars Transaction with Biocon Biologics Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon Biologics Marks the First in

Exhibit 99.1 Viatris Completes Biosimilars Transaction with Biocon Biologics Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon Biologics Marks the First in a Series of Expected Initiatives to Reshape and Rebase Viatris, Aimed at Setting it Up for Long-term Growth PITTSBURGH, Nov. 29, 2022 ?

Messages of certain officers of Viatris Inc. posted on LinkedIn on November 11, 2022

EX-99.1 2 d419178dex991.htm EX-99.1 Exhibit 99.1 The following communications are being filed in connection with the proposed acquisition of Oyster Point Pharma, Inc. by a wholly owned subsidiary of Viatris Inc. (“Viatris”). Michael Goettler, Chief Executive Officer of Viatris, posted the following message on LinkedIn on November 11, 2022: We made some exciting announcements earlier this week! In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHA

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Se

Viatris Q3’22 November 7, 2022

EX-99.1 Exhibit 99.1 The following is an excerpt from the script for the conference call that was held at 8:30 a.m. Eastern Time on November 7, 2022, by Viatris Inc. The following does not purport to be a complete statement or summary of the conference call. Viatris Q3’22 November 7, 2022 Corporate Speakers: • William Szablewski; Senior Key Executive; Viatris Inc. • Robert Coury; Chairman of the B

Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event

EX-99.1 Exhibit 99.1 Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event • Expects Biocon Biologics Transaction to Close Shortly • Intends to Begin Executing on Stock Repurchase Program • Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $70

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exa

Viatris Reports Strong Third Quarter 2022 Results

Viatris Reports Strong Third Quarter 2022 Results •Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to Date •Reports Total Revenues of $4.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OYSTER POINT PHARMA, INC. (Name of Subject Company) IRIS PURCHASER INC. (Offeror) A Wholly Owned Subsidiary of VIATRIS INC. (Parent of Offeror) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 VIATRIS INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Portions of Viatris Investor Presentation, dated November 7, 2022.

Strategic Update: Our Path to Return to Growth November 7, 2022 Exhibit 99.1 This presentation contains ?forward-looking statements?. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, 2022 financial guidance; our outlooks and expectations with respect to the end

IMPORTANT INFORMATION

EX-99.2 Exhibit 99.2 Script of Viatris’ Executive Chairman’s “State of the Union” message from the conference call and live webcast held at 8:30am November 7, 2022, providing a strategic update on Viatris’ February 2022 investor event. Introduction Good morning – almost two years ago today, we brought together two great complementary organizations to form a new company, Viatris, with the purpose o

Press Release issued by Viatris Inc., dated November 7, 2022 (incorporated by reference to Exhibit 99.2 of Viatris Inc.’s Schedule TO filed with the SEC on November 7, 2022).

Exhibit 99.2 Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event ? Expects Biocon Biologics Transaction to Close Shortly ? Intends to Begin Executing on Stock Repurchase Program ? Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $700-$750 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

COURTESY DEF 14A

Annual Meeting of Shareholders 2022 Proxy Statement

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

EX-22 2 ex22xvtrsx20220630.htm EX-22 Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of June 30, 2022, Viatris Inc., a Delaware corporation (“Viatris”), Mylan Inc., a Pennsylvania corporation (“Mylan Inc.”), and Mylan II B.V., a company incorporated under the laws of the Netherlands (“Mylan II”), were the guarantors of the 3.950% Senior Notes due 2026 and 5.250% Se

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact na

* * *

1000 Mylan Boulevard Canonsburg, PA 15317 Phone: 724.514.1800 August 8, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Vanessa Robertson and Kevin Vaughn, Division of Corporation Finance, Office of Life Sciences Re: Viatris Inc. Form 10-K for the Fiscal Year Ended December

Viatris Reports Strong Second Quarter 2022 Results

Viatris Reports Strong Second Quarter 2022 Results ?Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million; and Free Cash Flow of $719 Million ?Strong First Half 2022 Cash Flow; Approximately $1.9 Billion of U.S. GAAP Net Cash Provided by Operating Activities and Approxim

Viatris Reports Strong First-Quarter 2022 Results

Viatris Reports Strong First-Quarter 2022 Results ?First-Quarter 2022 Results Reflect Strong Operational Start to the Year ?Total Revenues Were $4.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact n

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

As filed with the Securities and Exchange Commission on May 6, 2022

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2022 Registration No.

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Viatris Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo

Consent of Parker Poe Adams & Bernstein LLP (included as part of Exhibit 5.3).

Exhibit 5.3 May 6, 2022 Viatris Inc. Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Re: The Registration Statement (as defined below) Ladies and Gentlemen: We are Pennsylvania counsel to Mylan Inc., a Pennsylvania corporation (?Company?), and have been asked to prepare and deliver this opinion letter in connection with the Company?s proposed guarantees (collectively, ?Debt Securiti

Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of The Bank of New York Mellon, as trustee, with respect to the Form of Viatris Inc. Indenture.

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Jurisdiction

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Viatris Inc. (Exact Name of Registrant as Specified in Its Charter) Mylan Inc. (Exact Name of Registrant as Specified in Its Charter) Mylan II B.V. (Exact Name of Registrant as Specified in Its Charter) Utah Acquisition Sub Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Secu

As filed with the Securities and Exchange Commission on May 6, 2022

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2022 Registration No.

Form of Indenture among Viatris Inc., as issuer, the guarantors party thereto and The Bank of New York Mellon, as trustee (the “Form of Viatris Inc. Indenture”).

Exhibit 4.9 VIATRIS INC. INDENTURE Dated as of , THE BANK OF NEW YORK MELLON as Trustee Table Showing Reflection in Indenture of Certain Provisions of Trust Indenture Act of 1939, as amended* Reflected in Indenture Trust Indenture Act Section Indenture Section 310 (a) (1) 7.09 (a) (2) 7.09 (a) (3) N.A. (a) (4) N.A. (a) (5) 7.09 (b) 7.03; 7.09 311 (a) 7.11 (b) 7.11 312 (a) 2.07 (b) 12.05 (c) 12.05

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ Transition R

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2021 OR ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file numbe

Subsidiaries as of December 31, 2021

Exhibit 21 Subsidiaries as of December 31, 2021 Name State or Country of Organization Agila Australasia Pty Ltd Australia Alphapharm Pty.

List of subsidiary guarantors and issuers of guaranteed securities, filed as Exhibit 22 to the Report on Form 10-K filed by Viatris Inc. with the SEC on February 28, 2022, and incorporated herein by reference.

Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of December 31, 2021, Viatris Inc.

Transaction Agreement, dated as of February 27, 2022, by and among Biocon Biologics Limited and Viatris Inc.*

Exhibit 2.1 [EXECUTION VERSION] TRANSACTION AGREEMENT by and between BIOCON BIOLOGICS LIMITED and VIATRIS INC. Dated as of February 27, 2022 TABLE OF CONTENTS Page ARTICLE I The Closing 2 SECTION 1.01. Closing 2 SECTION 1.02. ROW Acquisition; Irish Subscription; Irish Redemption 3 SECTION 1.03. Allocation of Cash Consideration and Acquired Equity Interests 3 SECTION 1.04. Transactions to be Effect

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results and Issues 2022 Financial Guidance Completes Comprehensive Strategic Review and Unveils Plan to Reshape the Company for the Future Announces Combination of its Biosimilars Por

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results and Issues 2022 Financial Guidance Completes Comprehensive Strategic Review and Unveils Plan to Reshape the Company for the Future Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2021 OR ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact name o

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

VTRS / Viatris Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Viatris Inc. Title of Class of Securities: Common Stock CUSIP Number: 92556V106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule 13d-1

VTRS / Viatris Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Viatris Inc (Name of Issuer) Common Stock (Title of Class of Securities) 92556V106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022 Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share

Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022 Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-39695 VIATRIS INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

VIATRIS INC. OFFER TO EXCHANGE Up to $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022 CUSIP #91533BAA8, ISIN #US91533BAA89 CUSIP #U9156BAA3, ISIN #USU9156BAA36 (the “2022 Restricted Notes”) for a like aggregate principal amou

Table of Contents Filed pursuant to Rule 424(b)(3) Registration Number 333-259463 PROSPECTUS VIATRIS INC.

Viatris Inc. Utah Acquisition Sub Inc. Mylan II B.V. Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 (724) 514-1800

CORRESP 1 filename1.htm Viatris Inc. Utah Acquisition Sub Inc. Mylan II B.V. Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 (724) 514-1800 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 September 24, 2021 Registration Statement on Form S-4 File No. 333-259463 Dear Sir or Madam: In accordance with

Form of Letter of Transmittal relating to the $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022, $750,000,000 aggregate principal amount of 1.650% Senior Notes due 2025, $750,000,000 aggregate principal amount of 2.300% Senior Notes due 2027, $1,450,000,000 aggregate principal amount of 2.700% Senior Notes due 2030, $1,500,000,000 aggregate principal amount of 3.850% Senior Notes due 2040 and $2,000,000,000 aggregate principal amount of 4.000% Senior Notes due 2050.

Exhibit 99.3 LETTER OF TRANSMITTAL VIATRIS INC. OFFER TO EXCHANGE Up to $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022 CUSIP #91533BAA8, ISIN #US91533BAA89 CUSIP #U9156BAA3, ISIN #USU9156BAA36 for a like aggregate principal amount of 1.125% Senior Notes due 2022 which have been registered under the Securities Act of 1933, as amended; Up to $750,000,000 aggregate principa

Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of The Bank of New York Mellon with respect to the Indenture dated as of June 22, 2020.

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Jurisdiction

As filed with the Securities and Exchange Commission on September 10, 2021

Table of Contents As filed with the Securities and Exchange Commission on September 10, 2021 Registration No.

Consent of Thomas D. Salus, Assistant Secretary of Viatris Inc. and Deputy Global General Counsel and Assistant Secretary of Mylan Inc. (included in Exhibit 5.3).

Exhibit 5.3 September 10, 2021 Viatris Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Ladies and Gentlemen: I am the Assistant Secretary of Viatris Inc., a Delaware corporation (the ?Company?), and the Deputy Global General Counsel and Assistant Secretary of Mylan Inc., a Pennsylvania corporation (the ?Pennsylvania Guarantor?), and am rendering this opinion in connection with the filing

List of Guarantor Subsidiaries.

Exhibit 22.1 List of Subsidiary Guarantors As of September 10, 2021, the following entities were guarantors of the 1.125% Senior Notes due 2022, 1.650% Senior Notes due 2025, 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050, each issued by Viatris Inc.: Name of Entity Jurisdiction of Organization or Formation Utah Acquisition

Acknowledgment letter of KPMG LLP relating to the unaudited condensed combined financial statements of the Upjohn Business.

Exhibit 15.1 KPMG LLP 345 Park Avenue New York, NY 10154 September 10, 2021 Re: Registration Statement on Form S-4 of Viatris Inc. With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated December 23, 2020 related to our review of interim financial information of Upjohn (formerly a business unit of Pfizer Inc.). Pursuant to Rule 436 un

Third Amended and Restated Bylaws, as Amended, of Mylan Inc.

Exhibit 3.8 MYLAN INC. (a Pennsylvania corporation) THIRD AMENDED AND RESTATED BYLAWS, AS AMENDED Adopted as of October 24, 2002, and amended on June 19, 2003, October 28, 2003, February 18, 2005, October 2, 2007, December 17, 2007, May 7, 2009, and September 26, 2017 ARTICLE I OFFICES AND FISCAL YEAR Section 1.01 Registered Office. The registered office of Mylan Inc. (the ?Corporation?) in the Co

Amended and Restated Articles of Incorporation, as Amended, of Mylan Inc.

Exhibit 3.7 MYLAN INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION, AS AMENDED 1. The name of the corporation is Mylan Inc. 2. The name of its commercial registered office provider and county of venue is c/o Corporation Service Company, Washington County, Pennsylvania. 3. The corporation is incorporated under the provisions of the Business Corporation Law. 4. The aggregate number of shares whic

Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees relating to the $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022, $750,000,000 aggregate principal amount of 1.650% Senior Notes due 2025, $750,000,000 aggregate principal amount of 2.300% Senior Notes due 2027, $1,450,000,000 aggregate principal amount of 2.700% Senior Notes due 2030, $1,500,000,000 aggregate principal amount of 3.850% Senior Notes due 2040 and $2,000,000,000 aggregate principal amount of 4.000% Senior Notes due 2050.

Exhibit 99.2 VIATRIS INC. OFFER TO EXCHANGE Up to $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022 CUSIP #91533BAA8, ISIN #US91533BAA89 CUSIP #U9156BAA3, ISIN #USU9156BAA36 for a like aggregate principal amount of 1.125% Senior Notes due 2022 which have been registered under the Securities Act of 1933, as amended; Up to $750,000,000 aggregate principal amount of 1.650% Sen

Certificate of Incorporation of Utah Acquisition Sub Inc.

Exhibit 3.4 CERTIFICATE OF INCORPORATION of UTAH ACQUISITION SUB INC. I, the undersigned, for the purpose of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, do hereby execute this Certificate of Incorporation and do hereby certify as follows: ARTICLE I The name of the corporation is Utah Acquisition Sub Inc. (the ?Corporation?). ARTICLE II The

Deed of Incorporation of Mylan II B.V.

Exhibit 3.6 DEED OF INCORPORATION MYLAN II B.V. (informal translation) On this day, the twenty-fifth day of July two thousand and nineteen, appeared before me, Paul Cornelis Simon van der Bijl, civil law notary in Amsterdam: Dani?l Michel Hagelstein, employed at the offices of me, civil law notary, located at 1082 PR Amsterdam, the Netherlands, Beethovenstraat 400, born in Wageningen, the Netherla

Form of Letter to Clients relating to the $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022, $750,000,000 aggregate principal amount of 1.650% Senior Notes due 2025, $750,000,000 aggregate principal amount of 2.300% Senior Notes due 2027, $1,450,000,000 aggregate principal amount of 2.700% Senior Notes due 2030, $1,500,000,000 aggregate principal amount of 3.850% Senior Notes due 2040 and $2,000,000,000 aggregate principal amount of 4.000% Senior Notes due 2050.

Exhibit 99.1 VIATRIS INC. OFFER TO EXCHANGE Up to $1,000,000,000 aggregate principal amount of 1.125% Senior Notes due 2022 CUSIP #91533BAA8, ISIN #US91533BAA89 CUSIP #U9156BAA3, ISIN #USU9156BAA36 for a like aggregate principal amount of 1.125% Senior Notes due 2022 which have been registered under the Securities Act of 1933, as amended; Up to $750,000,000 aggregate principal amount of 1.650% Sen

Bylaws of Utah Acquisition Sub Inc.

Exhibit 3.5 EXECUTION VERSION BY-LAWS of UTAH ACQUISITION SUB INC. dated as of July 25, 2019 TABLE OF CONTENTS ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE 1 SECTION 2. OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS SECTION 1. ANNUAL MEETINGS 1 SECTION 2. SPECIAL MEETINGS 1 SECTION 3. VOTING 1 SECTION 4. QUORUM 2 SECTION 5. NOTICE OF MEETINGS 2 SECTION 6. ACTION WITHOUT MEETING 2 ARTICLE II

Viatris Reports Strong Second Quarter Results Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share Company Raises 2021 Financial Guidance

EX-99.1 2 exhibit991-2q21earningsrel.htm EX-99.1 Viatris Reports Strong Second Quarter Results Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share Company Raises 2021 Financial Guidance PITTSBURGH – August 9, 2021 •Reports Second Quarter 2021 Financial Results - Total Revenues of $4.58 billion, U.S. GAAP Net Loss of $279 million, Adjusted EBITDA of $1.68 billion, U.S.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-39695 VIATRIS INC. (Exact nam

Amended and Restated Revolving Credit Agreement, dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders and issuing banks from time to time party thereto and Bank of America, N.A., as administrative agent.*

Exhibit 10.1 EXECUTION VERSION Deal CUSIP Number: 92557HAA4 Facility CUSIP Number: 92557HAB2 AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT dated as of JULY 1, 2021 among VIATRIS INC. as Borrower and the Guarantors from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent and the Lenders and the Issuing Banks from time to time party hereto BofA SECURITIES, INC., BARCLAYS B

Term Loan Credit Agreement, dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent.*

EX-10.2 3 d50384dex102.htm EX-10.2 Exhibit 10.2 TERM LOAN CREDIT AGREEMENT dated as of JULY 1, 2021 among VIATRIS INC., as Borrower and the Guarantors from time to time party hereto and MIZUHO BANK, LTD., as Administrative Agent and the Lenders from time to time party hereto MIZUHO BANK, LTD. and MUFG BANK, LTD. as Mandated Lead Arrangers and Book Runners MUFG BANK, LTD. as Syndication Agent TABLE

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend

EX-99.1 2 exhibit991-1q21earningsrel.htm EX-99.1 Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend PITTSBURGH - May 10, 2021: •Reports First Quarter 2021 Financial Results - Total Revenue of $4.4 billion, U.S. GAAP net loss of $1.0 billion, Adjusted EBITDA of $1.6 billion, U.S. GAAP net cash provided by operating ac

VIATRIS INC. PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT

Exhibit 10.2 VIATRIS INC. PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT THIS PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (this ?Agreement?), dated as of [] (the ?Date of Grant?), is made by and between Viatris Inc., a Delaware corporation (the ?Company?), and [] (the ?Participant?). 1.Grant of Performance-Based Restricted Stock Units. (a)Grant. The Company hereby grants to th

VIATRIS INC. DIRECTOR RESTRICTED STOCK UNIT AWARD AGREEMENT

EX-10.3 4 ex103xvtrsx20210331x10-q.htm EX-10.3 Exhibit 10.3 VIATRIS INC. DIRECTOR RESTRICTED STOCK UNIT AWARD AGREEMENT THIS DIRECTOR RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of [] (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [] (the “Participant”) in respect of Participant’s service as a member of the Board of Di

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-39695 VIATRIS INC. (Exact na

VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT

EX-10.1 2 ex101xvtrsx20210331x10-q.htm EX-10.1 Exhibit 10.1 VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of [] (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [] (the “Participant”). 1.Grant of Restricted Stock Units. (a)Grant. The Company hereby grants to the Parti

10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number 001-39695 VIAT

Retention Agreement entered into on December 3, 2020, by and between Viatris Inc. and Anthony Mauro.*

EX-10.1 2 d113011dex101.htm EX-10.1 Exhibit 10.1 December 3, 2020 Anthony Mauro c/o Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Re: Retention Agreement Dear Mr. Mauro: As you know, Mylan N.V. (“Mylan”) and Upjohn Inc. (“Upjohn”) consummated the combination of Mylan and Upjohn pursuant to the Business Combination Agreement between Pfizer Inc., Upjohn, Mylan and the other parties

[Pfizer Inc. Letterhead]

EX-10.2 9 ex102-vtrsx20201231x10xk.htm EX-10.2 Exhibit 10.2 [Pfizer Inc. Letterhead] February 6, 2020 Confidential Sanjeev Narula 235 East 42nd Street New York, NY 10017 Re: Clarification and Amendment of Upjohn Retention and Incentive Program Letter Dear Sanjeev: As you know, Pfizer Inc. (“Pfizer”), Upjohn Inc. (“Upjohn”) and Mylan N.V. (“Mylan”), among other parties, entered into a Business Comb

[Pfizer Letterhead]

Exhibit 10.5 [Pfizer Letterhead] July 29, 2019 Confidential Michael Goettler 235 East 42nd Street New York, NY 10017 Re: Upjohn Deal Completion Bonus Dear Michael: On behalf of Pfizer Inc (together with its subsidiaries and affiliates, collectively referred to herein, as ?Pfizer? or the ?Company?), we are pleased to inform you that the Company has determined to provide you with a special ?Deal Com

[Pfizer Inc. Letterhead]

Exhibit 10.3 [Pfizer Inc. Letterhead] June 25, 2019 Confidential Sanjeev Narula 235 East 42nd Street New York, NY 10017 Re: Upjohn Retention and Incentive Program Dear Sanjeev: On behalf of Pfizer Inc (together with its subsidiaries and affiliates, collectively referred to herein, as ?Pfizer? or the ?Company?), we are pleased to inform you that based on your current role on the Upjohn Leadership T

[remainder of page intentionally left blank; signature page follows]

Exhibit 10.6 December 3, 2020 Michael Goettler c/o Viatris Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Dear Mr. Goettler: As you know, Upjohn Inc. (?Upjohn?) and Mylan N.V. (?Mylan?) consummated the combination of Mylan and Upjohn pursuant to the Business Combination Agreement between Pfizer Inc., Upjohn, Mylan and the other parties thereto to create Viatris Inc. (?Viatris?), a new ch

Amended and Restated Bylaws of Viatris Inc., effective as of November 16, 2020, filed as Exhibit 3.2 to the Report on Form 10-K filed by Viatris Inc. with the SEC on March 1, 2021, and incorporated herein by reference.

EX-3.2 2 ex32-vtrsx20201231x10k.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VIATRIS INC. Effective as of November 16, 2020 Table of Contents Page ARTICLE I STOCKHOLDERS’ MEETINGS 1 Section 1.1 Place of Meetings 1 Section 1.2 Annual Meetings 1 Section 1.3 Special Meetings 1 Section 1.4 Notice 2 Section 1.5 Quorum; Adjournments; Postponement 2 Section 1.6 Proxies; Voting 3 Section 1.7 Insp

[remainder of page intentionally left blank]

Exhibit 10.8 December 3, 2020 Anthony Mauro c/o Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Re: Retention Agreement Dear Mr. Mauro: As you know, Mylan N.V. (?Mylan?) and Upjohn Inc. (?Upjohn?) consummated the combination of Mylan and Upjohn pursuant to the Business Combination Agreement between Pfizer Inc., Upjohn, Mylan and the other parties thereto to create Viatris Inc. (the

[Pfizer Inc. Letterhead]

EX-10.4 11 ex104-vtrsx20201231x10xk.htm EX-10.4 Exhibit 10.4 [Pfizer Inc. Letterhead] June 26, 2019 Confidential Michael Goettler 235 East 42nd Street New York, NY 10017 Re: Upjohn Retention and Incentive Program Dear Michael: On behalf of Pfizer Inc (together with its subsidiaries and affiliates, collectively referred to herein, as “Pfizer” or the “Company”), we are pleased to inform you that bas

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

EX-22 19 ex22-vtrsx20201231x10xk.htm EX-22 Exhibit 22 List of Subsidiary Guarantors and Issuers of Guaranteed Securities As of December 31, 2020, Viatris Inc., a Delaware corporation (“Viatris”), Mylan Inc., a Pennsylvania corporation (“Mylan Inc.”), and Mylan II B.V., a company incorporated under the laws of the Netherlands (“Mylan II”), were the guarantors of the 3.150% Senior Notes due 2021, 3.

[remainder of page intentionally left blank]

EX-10.7 14 ex107-vtrsx20201231x10xk.htm EX-10.7 Exhibit 10.7 December 3, 2020 Rajiv Malik c/o Mylan Inc. 1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 Re: Retention Agreement Dear Mr. Malik: As you know, Mylan N.V. (“Mylan”) and Upjohn Inc. (“Upjohn”) consummated the combination of Mylan and Upjohn pursuant to the Business Combination Agreement between Pfizer Inc., Upjohn, Mylan and the othe

FORM OF INDEMNIFICATION AGREEMENT

EX-10.25 17 ex1025-vtrsx20201231x10xk.htm EX-10.25 Exhibit 10.25 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ], between Viatris Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). WHEREAS, the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Incorporation”) and the Amended

VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT

EX-10.1(C) 5 ex101c-vtrsx20201231x10xk.htm EX-10.1(C) Exhibit 10.1(c) VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of [] (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [] (the “Participant”). WHEREAS, Pfizer Inc. (“Pfizer”), Upjohn Inc. (“Upjohn”), Mylan N.V. (“Myl

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number 001-39695 VIATRIS INC. (Exact name

Exhibit 4.10

Exhibit 4.10 DESCRIPTION OF VIATRIS INC. SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2020, our shares of common stock, par value $0.01, are the only securities of Viatris Inc. (?Viatris?, ?we?, ?our? or ?us?) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following description of our common stock, referred

VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT

EX-10.1(D) 6 ex101d-vtrsx20201231x10xk.htm EX-10.1(D) Exhibit 10.1(d) VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of November 20, 2020 (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [] (the “Participant”). Capitalized terms used but not defined herein shall have t

[Signature page follows]

EX-10.9 16 ex109-vtrsx20201231x10xk.htm EX-10.9 Exhibit 10.9 This Executive Employment Agreement (this “Agreement”) is entered into on November 20, 2020, by and between Viatris Inc. (the “Company”) and Robert J. Coury (the “Executive”). RECITALS: WHEREAS, pursuant to the Business Combination Agreement, dated as of July 29, 2019 (the “Business Combination Agreement”), as amended, by and among Pfize

AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT

Exhibit 10.34(b) AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this ?Agreement?), is made as of November 5, 2020, by and between Mylan Ireland Limited, a company incorporated in Ireland and Aspen Global Incorporated, a company incorporated in Mauritius (registered number 078138) (collectively, the ?Parties?). WHEREAS, the Parties entered into that ce

VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT

EX-10.1(B) 4 ex101b-vtrsx20201231x10xk.htm EX-10.1(B) Exhibit 10.1(b) VIATRIS INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), dated as of [] (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [] (the “Participant”). Capitalized terms used but not defined herein shall have the meaning ascr

Viatris Inc. Value Creation Incentive Award Performance-Based Restricted Stock Unit Award Agreement

EX-10.1(E) 7 ex101e-vtrsx20201231x10xk.htm EX-10.1(E) Exhibit 10.1(e) Viatris Inc. Value Creation Incentive Award Performance-Based Restricted Stock Unit Award Agreement Viatris Inc. (the “Company”) hereby grants to ROBERT J. COURY (the “Participant”), effective as of November 23, 2020 (the “Grant Date”), the performance-based restricted stock unit award (the “Performance RSUs”) as set forth in th

Subsidiaries as of December 31, 2020

Exhibit 21 Subsidiaries as of December 31, 2020 Name State or Country of Organization Agila Australasia Pty Ltd Australia Alphapharm Pty.

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 4) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation)

Key References and U.S. GAAP Measures The measures described herein are calculated as indicated, are reflected as approximations and/or with rounding, and do not reflect final actual results or pro forma results in accordance with ASC 805 or Article

EX-99.1 VIATRIS February 22, 2021 Exhibit 99.1 Forward Looking Statements This presentation contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements with respect to 2021 financial guidance, diversity of and investment in

Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments

EX-99.2 Exhibit 99.2 Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments PITTSBURGH, February 22, 2021 – Viatris Inc. (NASDAQ: VTRS) today announced its 2021 financial guidance and reaffirmed its commitment to rapid de-leveraging, to enhancing and growing free cash flows, particularly following the phasing out of one-time and other stand up costs, to in

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation) (Commission File Num

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIATRIS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92556V106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF MYLAN AND THE UPJOHN BUSINESS

EX-99.2 4 d321704dex992.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF MYLAN AND THE UPJOHN BUSINESS On November 16, 2020, Viatris Inc., formerly known as Upjohn Inc. (“Viatris”), Mylan N.V. (“Mylan”) and Pfizer Inc. (“Pfizer”) announced that they had consummated the previously announced combination of Mylan with Pfizer’s off-patent branded and generic est

Upjohn (A Business Unit of Pfizer Inc.) Condensed Combined Financial Statements as of September 27, 2020 and for the Nine Months Ended September 27, 2020 and September 29, 2019 and Condensed Combined Balance Sheet as of December 31, 2019 and Independ

EX-99.1 3 d321704dex991.htm EX-99.1 Table of Contents Exhibit 99.1 Upjohn (A Business Unit of Pfizer Inc.) Condensed Combined Financial Statements as of September 27, 2020 and for the Nine Months Ended September 27, 2020 and September 29, 2019 and Condensed Combined Balance Sheet as of December 31, 2019 and Independent Auditors’ Review Report Table of Contents Index to Unaudited Condensed Combined

Financial Statements and Exhibits - 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 3) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation)

Acknowledgment letter of KPMG LLP relating to the unaudited condensed combined financial statements the Upjohn Business.

EX-15.1 Exhibit 15.1 KPMG LLP 345 Park Avenue New York, NY 10154 January 29, 2021 Re: Registration Statement No. 333-234337 With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated December 23, 2020 related to our review of interim financial information. Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is no

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Viatris Inc. Title of Class of Securities: Common Stock CUSIP Number: 92556V106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 001-39695 83-4364296 (State or Other Jurisdiction of Incorporation)

Letter from KPMG LLP, dated November 25, 2020.

EX-16.1 KPMG LLP 345 Park Avenue New York, NY 10154-0102 November 25, 2020 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Viatris Inc., formerly known as Upjohn Inc. (the Company), and, under the date of May 7, 2020, we reported on the consolidated balance sheet of Upjohn Inc. and subsidiaries as of December 31, 2019, th